With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, ...

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

A mid-stage study for ABI-5366 will begin mid next year, while Assembly continues to assess the Phase II potential of ...

For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including ...

Structure's aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech's stock up nearly 103% as ...

TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech ...

Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week ...

At the heart of the deal is Relation’s Lab-in-the-Loop platform, which uses AI models to improve understanding of diseases ...

What China is accomplishing in R&D “has implications for everyone playing in the R&D or innovation world,” McKinsey’s ...

Although still in Phase I, Wave Life Sciences’ injectable RNA weight loss treatment achieved results that impressed analysts, ...

Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...